US Food and Drug Administration's Approval of Aripiprazole Tablets With Sensor: Our Perspective

J Clin Psychiatry. 2018 May/Jun;79(3):18com12255. doi: 10.4088/JCP.18com12255.

Authors

Daniel J Lee¹, Tiffany R Farchione¹, Mitchell V Mathis¹, Javier Muniz¹, Brendan M Muoio^{2

1}

Affiliations

¹ Division of Psychiatry Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
² Division of Psychiatry Products, US Food and Drug Administration, Bldg 22, Ste 4114, 10903 New Hampshire Ave, Silver Spring, MD 20993. brendan.muoio@fda.hhs.gov.

PMID: 29873960
DOI: 10.4088/JCP.18com12255

No abstract available

Publication types

Review

MeSH terms

Antipsychotic Agents / administration & dosage*
Aripiprazole / administration & dosage*
Biosensing Techniques* / ethics
Bipolar Disorder / drug therapy*
Depressive Disorder, Major / drug therapy*
Drug Approval*
Humans
Privacy* / legislation & jurisprudence
Schizophrenia / drug therapy*
Tablets*
United States
United States Food and Drug Administration*

Substances

Antipsychotic Agents
Tablets
Aripiprazole